E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer

被引:129
作者
Oeggerli, M
Tomovska, S
Schraml, P
Calvano-Forte, D
Schafroth, S
Simon, R
Gasser, T
Mihatsch, MJ
Sauter, G
机构
[1] Univ Basel, Inst Pathol, CH-4031 Basel, Switzerland
[2] Inst Pathol, CH-4031 Basel, Switzerland
[3] Urol Clin, CH-4410 Liestal, Switzerland
关键词
bladder cancer; 6p22; E2F3; amplification; FISH; IHC;
D O I
10.1038/sj.onc.1207749
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
E2F3 is located in the 6p22 bladder amplicon and encodes a transcription factor important for cell cycle regulation and DNA replication. To further investigate the role of E2F3 in bladder cancer, a tissue microarray containing samples from 2317 bladder tumors was used for gene copy number and expression analysis by means of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). E2F3 amplification was strongly associated with invasive tumor phenotype and high tumor grade (P<0.0001 each). None of 272 pTaG1/G2 tumors, but 35 of 311 pT1-4 carcinomas (11.3%), had E2F3 amplification. A high E2F3 expression level was associated with high grade, advanced stage, and E2F3 gene amplification (P<0.0001 each). To evaluate whether E2F3 expression correlates with tumor proliferation, the Ki67 labeling index (LI) was analysed for each tumor. There was a strong association between a high Ki67 LI and E2F3 expression (P < 0.0001), which was independent of grade and stage. We conclude that E2F3 is frequently amplified and overexpressed in invasively growing bladder cancer (stage pT1-4). E2F3 expression appears to provide a growth advantage to tumor cells by activating cell proliferation in a subset of bladder tumors.
引用
收藏
页码:5616 / 5623
页数:8
相关论文
共 53 条
[21]  
Mostofi FK., 1973, HISTOLOGICAL TYPING
[22]   The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates [J].
Nakopoulou, L ;
Vourlakou, C ;
Zervas, A ;
Tzonou, A ;
Gakiopoulou, H ;
Dimopoulos, MA .
HUMAN PATHOLOGY, 1998, 29 (02) :146-154
[23]  
Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585
[24]  
Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO
[25]  
2-D
[26]   Comparative analysis of MiB1 and p53 expression in human bladder tumors and their correlation with cancer progression [J].
Pfister, C ;
Buzelin, F ;
Casse, C ;
Bochereau, G ;
Buzelin, JM ;
Bouchot, O .
EUROPEAN UROLOGY, 1998, 33 (03) :278-284
[27]  
Polanowska J, 2000, GENE CHROMOSOME CANC, V28, P126, DOI 10.1002/(SICI)1098-2264(200005)28:1<126::AID-GCC15>3.0.CO
[28]  
2-G
[29]   LOCALIZATION OF THE HUMAN ERB-2 GENE ON NORMAL AND REARRANGED CHROMOSOMES 17 TO BANDS Q12-21.32 [J].
POPESCU, NC ;
KING, CR ;
KRAUS, MH .
GENOMICS, 1989, 4 (03) :362-366
[30]   Prognostic significance of transcription factor E2F-1 in bladder cancer: Genotypic and phenotypic characterization [J].
Rabbani, F ;
Richon, VM ;
Orlow, I ;
Lu, ML ;
Drobnjak, M ;
Dudas, M ;
Charytonowicz, E ;
Dalbagni, G ;
Cordon-Cardo, C .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (10) :874-881